Lv12
60 积分 2026-01-18 加入
Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8. PMID: 31402114
21小时前
待确认
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
22小时前
已完结
Ketamine and botulinum: a safe combinationfor the management of childhood strabismus
2天前
已完结
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
14天前
已完结
Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study
14天前
已完结
51791 Guselkumab improves psoriatic skin and HRQoL outcomes across BMI subgroups, including patients with involvement of hard-to-treat areas: results from the real-world PERSIST study
1个月前
已关闭
Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial
1个月前
已完结
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
1个月前
已完结
Time to relapse after treatment withdrawal for different biologics used to treat plaque psoriasis
1个月前
已完结
皖公网安备34019202002308
